Small-cap biotech stocks offer high growth potential through groundbreaking research and novel therapeutic approaches. Astria Therapeutics (ATXS) focuses on hereditary angioedema (HAE) and atopic dermatitis, with a stock value down 30.7% year-to-date but predicted to rally 349% above current levels. Their lead asset, Navenibart, targets HAE with promising safety results.

Astria recently completed enrollment in a Phase 3 clinical trial for HAE, with top-line data expected in early 2027. They are also advancing STAR-0310 for atopic dermatitis. While facing high R&D expenses and a net loss due to being in the clinical stage, Astria secured funding until 2028 through a licensing agreement with Kaken Pharmaceutical.

Aardvark Therapeutics (AARD) focuses on developing small-molecule therapies for metabolic diseases by suppressing hunger. With a stock price down 31% year-to-date, AARD’s lead asset, ARD-101, targets rare hunger-related conditions like Prader-Willi syndrome and hypothalamic obesity. They are also working on ARD-201 for obesity weight maintenance, with clinical trials underway to address specific questions.

Cash balance of $141.8 million supports Aardvark’s operations until 2027, with ongoing Phase 3 HERO trial and Phase 2 obesity trials. Despite a net loss due to increased R&D expenses, AARD stock is rated a “Strong Buy” on Wall Street, with the potential to rally nearly 300% above current levels. High price estimates suggest a 490% increase over the next 12 months.

Read more at Yahoo Finance: 2 ‘Strong Buy’ Growth Stocks Offering 300% or Higher Upside